Increased malignancy risk in the cutaneous T-cell lymphoma patient population

Clinical Lymphoma and Myeloma

Volumn 8, Issue 2, 2008, Pages 100-105

  Brownell, Isaac ^a   Etzel, Carol J ^b   Yang, Deborah J ^c   Taylor, Sarah H ^b   Duvic, Madeleine ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Mycosis fungoides; S zary syndrome; Standardized incidence ratio; Tracheal cancer

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONFIDENCE INTERVAL; CUTANEOUS T CELL LYMPHOMA; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYCOSIS FUNGOIDES; MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PLEURA CANCER; PREVALENCE; PROSTATE CANCER; RECTUM CANCER; RETROPERITONEAL CANCER; RISK ASSESSMENT; SEZARY SYNDROME; THYROID CANCER; TIME SERIES ANALYSIS; TRACHEA CANCER; UTERUS CANCER; VULVA CANCER;

EID: 44649105766     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.011     Document Type: Article

References (24)

1. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999; 89:1240-4.
2. Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer 1999; 85:208-12.
3. Epstein EH Jr, Levin DL, Croft JD Jr, et al. Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 1972; 51:61-72.
4. Greene MH, Dalager NA, Lamberg SI, et al. Mycosis fungoides: epidemiologic observations. Cancer Treat Rep 1979; 63:597-606.
5. Cyr DP, Geokas MC, Worsley GH. Mycosis fungoides. Hematologic findings and terminal course. Arch Dermatol 1966; 94:558-73.
6. Pielop JA, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int J Dermatol 2003; 42:116-22.
7. Evans AV, Scarisbrick JJ, Child FJ, et al. Cutaneous malignant melanoma in association with mycosis fungoides. J Am Acad Dermatol 2004; 50:701-5.
8. Olsen EA, Delzell E, Jegasothy BV. Second malignancies in cutaneous T cell lymphoma. J Am Acad Dermatol 1984; 10(2 Pt 1):197-204.
9. Kantor AF, Curtis RE, Vonderheid EC, et al. Risk of second malignancy after cutaneous T-cell lymphoma. Cancer 1989; 63:1612-5.
10. Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007; 143:45-50.
11. Vakeva L, Pukkala E, Ranki A. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol 2000; 115:62-5.
12. Esteve J, Benhamou E, Raymond L. Statistical Methods in Cancer Research. Volume IV. Destructive epidemiology. IARC Sci Publ 1994; 128:1-302.
13. Simple Interactive Statistical Analysis [Web site]. Available at: http://home.clara.net/sisa/. Accessed: April 14, 2008.
14. Bagot M, Nikolova M, Schirm-Chabanette F, et al. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann N Y Acad Sci 2001; 941:31-8.
15. Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003; 102:4059-66.
16. Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Invest Dermatol 1995; 105(1 suppl):105S-9S.
17. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350:1978-88.
18. Kotz EA, Anderson D, Thiers BH. Cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2003; 17:131-7.
19. Perera FP. Molecular epidemiology: on the path to prevention? J Natl Cancer Inst 2000; 92:602-12.
20. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002; 3:193-215.
21. Smith BD, Wilson LD. Management of mycosis fungoides: part 2. Treatment. Oncology (Williston Park) 2003; 17:1419-28.
22. Licata AG, Wilson LD, Braverman IM, et al. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. Arch Dermatol 1995; 131:432-5.
23. Smoller BR, Marcus R. Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides. J Am Acad Dermatol 1994; 30(2Pt 1):201-4.
24. Kwong YL, Au WY, Ng MH, et al. Acute myeloid leukemia following psoralen with ultraviolet A therapy: a fluorescence in situ hybridization study. Cancer Genet Cytogenet 1997; 99:11-3.